Skip to main navigation Skip to search Skip to main content

Spontaneous bilateral haemothorax with haemopericardium secondary to rivaroxaban

  • Jiun Hao Yu
  • , Hao Hsuan Liu
  • , Ming Jer Hsieh
  • , I. Chang Hsieh
  • , Pao Hsien Chu
  • , Dong Yi Chen*
  • *Corresponding author for this work
  • Chang Gung Memorial Hospital
  • China Medical University Taichung
  • Chang Gung University

Research output: Contribution to journalJournal Article peer-review

2 Scopus citations

Abstract

What is known and objective: Although the risk of major bleeding with non-vitamin K antagonist oral anticoagulant (NOAC) is low, life-threatening bleeding can occur. Case summary: We report a case of an 81-year-old female with deep vein thrombosis who developed bilateral spontaneous haemothorax and haemopericardium after rivaroxaban therapy. Diagnostic thoracentesis revealed a grossly bloody pleural effusion. She was treated with factor eight inhibitor bypassing agent, but the result was not satisfactory. What is new and conclusion: To our knowledge, this is the first case report of a concomitant presentation of spontaneous bilateral haemothorax and haemopericardium due to rivaroxaban use. This case highlights the potential risk of major haemorrhagic complication of NOAC, which could be life-threatening and require emergent reversal.

Original languageEnglish
Pages (from-to)1175-1178
Number of pages4
JournalJournal of Clinical Pharmacy and Therapeutics
Volume45
Issue number5
DOIs
StatePublished - 01 10 2020
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2020 John Wiley & Sons Ltd

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • factor Xa inhibitors
  • haemopericardium
  • non-vitamin K antagonist oral anticoagulants
  • rivaroxaban
  • spontaneous haemothorax

Fingerprint

Dive into the research topics of 'Spontaneous bilateral haemothorax with haemopericardium secondary to rivaroxaban'. Together they form a unique fingerprint.

Cite this